Q3 a mixed bag for IT majors

The October-December quarter broadly marked a turning point for domestic IT firms, with signs of revival in discretionary spending and a healthy order book. This was met with some optimism by analysts as the quarter is seasonally a weak one due to furloughs.

While Infosys and Wipro exceeded Street expectations, TCS and HCLTech were not able to meet analysts’ forecasts. Despite robust deal wins, challenges in total contract value (TCV) conversion and sustained growth in emerging markets remain concerns for the industry.

Also ReadRIL’s O2C segment to pick up in FY26, say brokerages

Infosys and Wipro outperformed, buoyed by strong demand in financial services and growth in the Americas. TCS and HCLTech, however, faced seasonal weaknesses that tempered their performance. Infosys posted sequential revenue and profit growth, driven by improved demand in financial services across the US and Europe. MD & CEO Salil Parekh noted, “In the last quarter, we saw discretionary spending recover in US financial services. This quarter, we are witnessing similar trends in Europe, along with improving demand in US retail and consumer products.”

Also Read Infosys Q3 earnings on January 16:  Here are 4 key things the street is watching out for QSRs stare at another weak quarter in Q3 RIL Q3FY25 results: Brokerage expect flattish growth Modest Q3 on the cards for India Inc

Wipro reported a minor revenue uptick, surpassing expectations due to strong demand in the Americas and the BFSI sector. CEO Srini Pallia said: “Clients are cautiously optimistic, and we’re seeing a gradual return of discretionary spending.”

Conversely, TCS missed estimates on both revenue and profit, citing seasonal Q3 weaknesses. HCLTech reported sequential growth in revenue and operating margins, but fell short of analysts’ expectations.

Despite mixed earnings, all four companies reported robust deal wins. Infosys’ large deal TCV rose marginally to $2.5 billion from $2.4 billion in Q2. Parekh highlighted increased deal activity across financial services and retail sectors. TCS reported an impressive TCV of $10.2 billion, up from $8.6 billion in Q2. CEO K Krithivasan said: “This well-rounded performance spans industries, geographies, and service lines”.

HCLTech’s total deal value decreased slightly to $2.1 billion from $2.2 billion in Q2, reflecting shorter deal tenures. CEO C Vijayakumar said: “The shift toward shorter-tenure deals is moderating TCV,

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth